Results 121 to 130 of about 10,054 (222)

Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria

open access: yes, 2018
Chronic spontaneous urticaria (CSU) is defined by the appearance of wheals and a variable presence of angioedema which persists for at least 6 weeks. It represents the most common subtype of chronic urticaria and is gaining importance in civil society ...
Enrico Heffler   +4 more
core   +1 more source

Diagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in Portugal [PDF]

open access: yes, 2016
Chronic spontaneous urticaria is a complex disorder, of unclear etiology, easily diagnosed although often difficult to treat. It has a significant impact on the patients' quality of life and results in high direct and indirect costs.
COSTA, C   +3 more
core   +1 more source

Pityriasis Lichenoides: Comparison of Two Pediatric Patients and Its Relationships With Vaccines and Infections

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Pityriasis lichenoides (PL) is a benign, self‐limiting inflammatory condition, characterized by the appearance of papular, scaly, or necrotic lesions. Despite the rare incidence, clinicians should suspect its diagnosis in the presence of specific skin lesions and epidemiological contexts, as suggested by its association with infections and/or ...
Gregorio Serra   +7 more
wiley   +1 more source

Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease [PDF]

open access: yes, 2016
The basophil activation test showing CD63 up regulation could be a specific and sensitive in vitro complementary text to the in vivo autologous serum skin test for the activity assessment of the patients suffering autoimmune chronic spontaneous urticaria.
Mojal, Sergio   +16 more
core   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source

Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature

open access: yes, 2012
The cause of chronic spontaneous urticaria has been an enigma for decades, but the recognition of functional autoantibodies in some patients with the spontaneous chronic urticaria has opened up a new concept of autoimmune urticaria.
SEIDITA, Aurelio   +4 more
core   +1 more source

Uptake and Use of Biologic Therapies in Paediatric Immune‐Mediated Inflammatory Diseases: An Australian Population‐Based Study

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 7, July 2026.
ABSTRACT Purpose To quantify the real‐world use and describe characteristics of paediatric patients initiating biologic medicines for immune‐mediated inflammatory diseases (IMIDs). Methods Dispensing claims for Australians aged less than 18 years were used to examine uptake and use trends of nine biologic medicines used for the treatment of IMIDs. A 15%
Jun Ni Ho   +6 more
wiley   +1 more source

Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases

open access: yesThe Journal of Dermatology, Volume 53, Issue 7, Page 967-979, July 2026.
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, Volume 81, Issue 7, Page 2391-2402, July 2026.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Endotypes of chronic spontaneous urticaria and angioedema

open access: yesJournal of Allergy and Clinical Immunology
The current understanding of chronic spontaneous urticaria (CSU) suggests that a complex network of inflammatory pathways is involved in its pathogenesis. Recent development highlighted autoimmunity as one of the key pathogenic mechanisms of CSU. Two endotypes, type I autoallergic (associated with IgE antibodies against autoantigens) and type IIb ...
Dennis, Wong   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy